Association of HLA B‐ and T‐cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation
Pediatric Transplantation · 2024
DOI: 10.1111/petr.14773 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2024. Verfasst von Ann-Maria Gramkow und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Graft Survival, HLA Antigens. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Augustinus Fonden, Syddansk Universitet, Nyreforeningen.
Abstract (Originalsprache)
Background
Optimizing graft survival and diminishing human leukocyte antigen (HLA) sensitization are essential for pediatric kidney transplant recipients. More precise HLA matching predicting epitope mismatches could reduce alloreactivity. We investigated the association of predicted HLA B‐ and T‐cell molecular mismatches with the formation of de novo donor‐specific antibodies, HLA antibodies, rejection, and graft survival.
Methods
Forty‐nine pediatric kidney transplant recipients transplanted from 2009 to 2020 were retrospectively studied. Donors and recipients were high‐resolution HLA typed, and recipients were screened for HLA antibodies posttransplant. HLA‐EMMA (HLA Epitope MisMatch Algorithm) and PIRCHE‐II (Predicted Indirectly ReCognizable HLA Epitopes) predicted the molecular mismatches. The association of molecular mismatches and the end‐points was explored with logistic regression.
Results
Five recipients (11%) developed de novo donor‐specific antibodies. All five had de novo donor‐specific antibodies against HLA class II, with four having HLA‐DQ antibodies. We found no associations between PIRCHE‐II or HLA‐EMMA with de novo donor‐specific antibodies, HLA sensitization, graft loss, or rejection. However, we did see a tendency towards an increased odds ratio in PIRCHE‐II predicting de novo donor‐specific antibodies formation, with an odds ratio of 1.12 (95% CI: 0.99; 1.28) on HLA class II.
Conclusion
While the study revealed no significant associations between the number of molecular mismatches and outcomes, a notable trend was observed – indicating a reduced risk of dnDSA formation with improved molecular match. It is important to acknowledge, however, that the modest population size and limited observed outcomes preclude us from making definitive conclusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Molecular Medicine - Cancer and Inflammation, University of Southern Denmark, Odense, Denmark.
ORCID-Profile: Ann-Maria Gramkow, Helle C Thiesson, Pernille Koefoed-Nielsen
Förderung
- Augustinus Fonden
- Syddansk Universitet
- Nyreforeningen
Zitieren
APA
Gramkow, A. M., Baatrup, J. H., Gramkow, E. T., Thiesson, H. C., & Koefoed-Nielsen, P. (2024). Association of HLA B‐ and T‐cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation. Pediatric Transplantation. https://doi.org/10.1111/petr.14773
Vancouver
Gramkow AM, Baatrup JH, Gramkow ET, Thiesson HC, Koefoed-Nielsen P. Association of HLA B‐ and T‐cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation. Pediatric Transplantation. 2024. doi:10.1111/petr.14773
BibTeX
@article{Gramkow2024,
author = {Gramkow, Ann-Maria and Baatrup, Johanne H and Gramkow, Emilie T and Thiesson, Helle C and Koefoed-Nielsen, Pernille},
title = {Association of HLA B‐ and T‐cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation},
journal = {Pediatric Transplantation},
year = {2024},
doi = {10.1111/petr.14773}
}
EUVIMED